N-氨甲酰谷氨酸
外观
| 臨床資料 | |
|---|---|
| 商品名 | Carbaglu, Ucedane |
| 其他名稱 | (S)-2-ureidopentanedioic acid |
| AHFS/Drugs.com | Monograph |
| 核准狀況 | |
| 懷孕分級 |
|
| 给药途径 | By mouth |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物利用度 | 30% |
| 血漿蛋白結合率 | Undetermined |
| 药物代谢 | Partial |
| 生物半衰期 | 4.3 to 9.5 hours |
| 排泄途徑 | Fecal (60%) and kidney (9%, unchanged) |
| 识别信息 | |
| |
| CAS号 | 1188-38-1 |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.116.323 |
| 化学信息 | |
| 化学式 | C6H10N2O5 |
| 摩尔质量 | 190.16 g·mol−1 |
| 3D模型(JSmol) | |
| |
| |
N-氨甲酰谷氨酸(英語:Carglumic acid,商品名:Carbaglu等)是一种有机化合物,分子式C6H10N2O5,用于治疗高氨血症[3][6][7]。
参考文献
[编辑]- ^ Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始内容存档于2023-04-10).
- ^ Health Canada New Drug Authorizations: 2015 Highlights. Health Canada. 4 May 2016 [7 April 2024]. (原始内容存档于2020-02-20).
- ^ 3.0 3.1 Carbaglu- carglumic acid tablet. DailyMed. [9 June 2021]. (原始内容存档于2021-06-09).
- ^ Carbaglu EPAR. European Medicines Agency (EMA). 17 September 2018 [9 June 2021]. (原始内容存档于2021-06-09).
- ^ Ucedane EPAR. European Medicines Agency (EMA). 17 September 2018 [9 June 2021]. (原始内容存档于2021-06-09).
- ^ Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr. 2004, 145 (4): 552–4. PMID 15480384. doi:10.1016/j.jpeds.2004.06.047.
- ^ Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C. N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol. 2002, 52 (6): 845–9. PMID 12447942. S2CID 24604774. doi:10.1002/ana.10406
.